Phase II clinical study of modified FOLFOX7 (intermittent oxaliplatin administration) plus bevacizumab in patients with unresectable metastatic colorectal cancer—CRAFT study View Full Text


Ontology type: schema:ScholarlyArticle      Open Access: True


Article Info

DATE

2013-10

AUTHORS

Tohru Tezuka, Chikuma Hamada, Hideyuki Ishida, Mitsuru Ooshiro, Hiroshi Matsuoka, Shingo Kawasaki, Hideyuki Mishima, Kotaro Maeda, Junichi Sakamoto, Keiji Koda

ABSTRACT

PURPOSE: Continuous treatment with FOLFOX therapy is associated with peripheral nerve toxicity, and to improve this inconvenient side effect various methods of administration are being investigated. A regimen of intermittent oxaliplatin administration by continuous infusion therapy, i.e., modified FOLFOX7 (mFOLFOX7) + bevacizumab, was designed with the goal of alleviating severe peripheral nerve disorders and hematological toxicity. A phase II clinical study was conducted to evaluate the efficacy and safety of this regimen. METHODS: Previously untreated patients were assigned to mFOLFOX7 (oxaliplatin 85 mg/m(2), levofolinate [l-LV] 200 mg/m(2), 5-fluorouracil [5-FU] 2400 mg/m(2)) + bevacizumab (5 mg/kg) administered every 2 weeks for 8 cycles, maintenance without oxaliplatin for 8 cycles, and reintroduction of mFOLFOX7 + bevacizumab for 8 cycles or until disease progression. Progression free survival (PFS) following the first dose (PFS 1) and following reintroduction of oxaliplatin (PFS 2) were used as indices for assessing the efficacy of intermittent administration. RESULTS: Fifty-two patients were enrolled, with median age of 64 years (range, 36-74). Median PFS 1 was 11.8 months (95 % confidence interval [CI], 9.5 to 13.7), median time to treatment failure was 10.3 months (95 % CI, 5.6 to 12.1), percentage of patients with neutropenia of grade 3 or higher was 7.8 %, and percentage with peripheral nerve disorders was 3.9 %. Response rate was 50 %, and 84.4 % of patients who started modified simplified LV5FU2 + bevacizumab were reintroduced to oxaliplatin. CONCLUSION: By excluding 5-FU bolus administration and administering bevacizumab continuously the mFOLFOX7 + bevacizumab regimen with preplanned withdrawal of oxaliplatin showed high tolerability and prevented severe peripheral neuropathy and neutropenia without reducing efficacy. More... »

PAGES

1321-1329

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/s10637-013-9982-3

DOI

http://dx.doi.org/10.1007/s10637-013-9982-3

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1031173929

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/23817973


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1103", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Clinical Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Adult", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Angiogenesis Inhibitors", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Antibodies, Monoclonal, Humanized", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Antineoplastic Combined Chemotherapy Protocols", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Bevacizumab", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Colorectal Neoplasms", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Disease-Free Survival", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Female", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Fluorouracil", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Leucovorin", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Liver Neoplasms", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Lung Neoplasms", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Lymphatic Metastasis", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Male", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Middle Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Organoplatinum Compounds", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Peritoneal Neoplasms", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Treatment Outcome", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Teikyo University Chiba Medical Center", 
          "id": "https://www.grid.ac/institutes/grid.412406.5", 
          "name": [
            "Department of Surgery, Teikyo University Chiba Medical Center, 3426-3 Anesaki, 299-0111, Ichihara City, Chiba, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Tezuka", 
        "givenName": "Tohru", 
        "id": "sg:person.01275733574.41", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01275733574.41"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Tokyo University of Science", 
          "id": "https://www.grid.ac/institutes/grid.143643.7", 
          "name": [
            "Faculty of Engineering, Tokyo University of Science, Tokyo, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Hamada", 
        "givenName": "Chikuma", 
        "id": "sg:person.01217410624.11", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01217410624.11"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Jichi Medical University Saitama Medical Center", 
          "id": "https://www.grid.ac/institutes/grid.415020.2", 
          "name": [
            "Department of Digestive Tract and General Surgery, Saitama Medical Center, Saitama Medical University, Saitama, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Ishida", 
        "givenName": "Hideyuki", 
        "id": "sg:person.011026272202.54", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.011026272202.54"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Toho University", 
          "id": "https://www.grid.ac/institutes/grid.265050.4", 
          "name": [
            "Department of Surgery, Toho University Sakura Medical Center, Chiba, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Ooshiro", 
        "givenName": "Mitsuru", 
        "id": "sg:person.01154202243.44", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01154202243.44"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Fujita Health University Hospital", 
          "id": "https://www.grid.ac/institutes/grid.471500.7", 
          "name": [
            "Department of Surgery, Fujita Health University Hospital, Aichi, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Matsuoka", 
        "givenName": "Hiroshi", 
        "id": "sg:person.01125146312.67", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01125146312.67"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "name": [
            "Department of Surgery, Saishukan Hospital, Aichi, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Kawasaki", 
        "givenName": "Shingo", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Aichi Medical University", 
          "id": "https://www.grid.ac/institutes/grid.411234.1", 
          "name": [
            "Aichi Medical University Cancer Center, Aichi, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Mishima", 
        "givenName": "Hideyuki", 
        "id": "sg:person.01222363707.85", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01222363707.85"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Fujita Health University Hospital", 
          "id": "https://www.grid.ac/institutes/grid.471500.7", 
          "name": [
            "Department of Surgery, Fujita Health University Hospital, Aichi, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Maeda", 
        "givenName": "Kotaro", 
        "id": "sg:person.0765430572.94", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0765430572.94"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Tokai Central Hospital", 
          "id": "https://www.grid.ac/institutes/grid.460103.0", 
          "name": [
            "Tokai Central Hospital, Gifu, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Sakamoto", 
        "givenName": "Junichi", 
        "id": "sg:person.0673305153.34", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0673305153.34"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Teikyo University Chiba Medical Center", 
          "id": "https://www.grid.ac/institutes/grid.412406.5", 
          "name": [
            "Department of Surgery, Teikyo University Chiba Medical Center, 3426-3 Anesaki, 299-0111, Ichihara City, Chiba, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Koda", 
        "givenName": "Keiji", 
        "id": "sg:person.0647155176.80", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0647155176.80"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "https://doi.org/10.1016/s0140-6736(00)02034-1", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1006410174"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2012.43.6535", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1013021486"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2005.00.232", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1013477854"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1056/nejmoa032691", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1014051315"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/bjc.2011.201", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1017729876", 
          "https://doi.org/10.1038/bjc.2011.201"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s10637-011-9779-1", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1023072546", 
          "https://doi.org/10.1007/s10637-011-9779-1"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2009.23.4344", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1026343555"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2007.14.9898", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1027137405"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2007.14.9930", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1029489307"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2006.06.1317", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1036243573"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/sj.bjc.6600467", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1041567656", 
          "https://doi.org/10.1038/sj.bjc.6600467"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/sj.bjc.6600467", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1041567656", 
          "https://doi.org/10.1038/sj.bjc.6600467"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2005.07.113", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1046620703"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2005.07.113", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1046620703"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2012.42.5355", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1049732450"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2005.03.0106", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1050440893"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2004.09.046", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1051354561"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2000.18.16.2938", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1074684744"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://app.dimensions.ai/details/publication/pub.1074766959", 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.1987.5.10.1559", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1078843412"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2008.26.15_suppl.4010", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1079372980"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.1997.15.2.808", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1083054579"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2013-10", 
    "datePublishedReg": "2013-10-01", 
    "description": "PURPOSE: Continuous treatment with FOLFOX therapy is associated with peripheral nerve toxicity, and to improve this inconvenient side effect various methods of administration are being investigated. A regimen of intermittent oxaliplatin administration by continuous infusion therapy, i.e., modified FOLFOX7 (mFOLFOX7) + bevacizumab, was designed with the goal of alleviating severe peripheral nerve disorders and hematological toxicity. A phase II clinical study was conducted to evaluate the efficacy and safety of this regimen.\nMETHODS: Previously untreated patients were assigned to mFOLFOX7 (oxaliplatin 85 mg/m(2), levofolinate [l-LV] 200 mg/m(2), 5-fluorouracil [5-FU] 2400 mg/m(2)) + bevacizumab (5 mg/kg) administered every 2 weeks for 8 cycles, maintenance without oxaliplatin for 8 cycles, and reintroduction of mFOLFOX7 + bevacizumab for 8 cycles or until disease progression. Progression free survival (PFS) following the first dose (PFS 1) and following reintroduction of oxaliplatin (PFS 2) were used as indices for assessing the efficacy of intermittent administration.\nRESULTS: Fifty-two patients were enrolled, with median age of 64 years (range, 36-74). Median PFS 1 was 11.8 months (95 % confidence interval [CI], 9.5 to 13.7), median time to treatment failure was 10.3 months (95 % CI, 5.6 to 12.1), percentage of patients with neutropenia of grade 3 or higher was 7.8 %, and percentage with peripheral nerve disorders was 3.9 %. Response rate was 50 %, and 84.4 % of patients who started modified simplified LV5FU2 + bevacizumab were reintroduced to oxaliplatin.\nCONCLUSION: By excluding 5-FU bolus administration and administering bevacizumab continuously the mFOLFOX7 + bevacizumab regimen with preplanned withdrawal of oxaliplatin showed high tolerability and prevented severe peripheral neuropathy and neutropenia without reducing efficacy.", 
    "genre": "research_article", 
    "id": "sg:pub.10.1007/s10637-013-9982-3", 
    "inLanguage": [
      "en"
    ], 
    "isAccessibleForFree": true, 
    "isPartOf": [
      {
        "id": "sg:journal.1094201", 
        "issn": [
          "0167-6997", 
          "1573-0646"
        ], 
        "name": "Investigational New Drugs", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "5", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "31"
      }
    ], 
    "name": "Phase II clinical study of modified FOLFOX7 (intermittent oxaliplatin administration) plus bevacizumab in patients with unresectable metastatic colorectal cancer\u2014CRAFT study", 
    "pagination": "1321-1329", 
    "productId": [
      {
        "name": "readcube_id", 
        "type": "PropertyValue", 
        "value": [
          "94827cb9097beeddc89a47c84459e341555e1f92cbbe82b41ceebba7a6ad7529"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "23817973"
        ]
      }, 
      {
        "name": "nlm_unique_id", 
        "type": "PropertyValue", 
        "value": [
          "8309330"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/s10637-013-9982-3"
        ]
      }, 
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1031173929"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1007/s10637-013-9982-3", 
      "https://app.dimensions.ai/details/publication/pub.1031173929"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2019-04-11T13:07", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-uberresearch-data-dimensions-target-20181106-alternative/cleanup/v134/2549eaecd7973599484d7c17b260dba0a4ecb94b/merge/v9/a6c9fde33151104705d4d7ff012ea9563521a3ce/jats-lookup/v90/0000000367_0000000367/records_88222_00000000.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "http://link.springer.com/10.1007%2Fs10637-013-9982-3"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s10637-013-9982-3'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s10637-013-9982-3'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s10637-013-9982-3'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s10637-013-9982-3'


 

This table displays all metadata directly associated to this object as RDF triples.

293 TRIPLES      21 PREDICATES      69 URIs      41 LITERALS      29 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/s10637-013-9982-3 schema:about N0343742df6b0414dbe50706b23ca137e
2 N0c518c56dc724dcfa4425a348c25bf35
3 N111e82d523a54ead8a5bb6d22b2124e2
4 N203a8f1a49d44994ac680c679938f003
5 N35e592a850804e2bac311eec45ff3fbc
6 N3c79b902930e4320ae24ab581a21321f
7 N3d41f0924b0c4a6e8af99257b178b4ad
8 N55d0a66af6b741e28b4f601890e218e5
9 N65272cc743b94695bb1bf8cfa2e2c43c
10 N6a606ecabdfa45a8bd7090e18757470f
11 N6f904dd56ad7448886960bd2270d3d1a
12 N95e0a2ad48e449c4a5c2f0ac0e3f5742
13 Naaf87db767be4f6a823af33d7331f5bf
14 Nc03ea8a03e684531a685bd1ea36280b2
15 Nd1b7291f816740e5bb558b311a079f70
16 Nd920c986b4b144829c6178afbffad324
17 Nde6fbffef5094286829fafdbb2dbd897
18 Ne7f84f811c7c45c9940e359b092adde4
19 Nf313e985d68946dbbda2982ce0ac8a89
20 Nf342520becfb4d0e95b91bfc8fdb7199
21 anzsrc-for:11
22 anzsrc-for:1103
23 schema:author N162bd330f0a3431a9455d52d9cf74cfb
24 schema:citation sg:pub.10.1007/s10637-011-9779-1
25 sg:pub.10.1038/bjc.2011.201
26 sg:pub.10.1038/sj.bjc.6600467
27 https://app.dimensions.ai/details/publication/pub.1074766959
28 https://doi.org/10.1016/s0140-6736(00)02034-1
29 https://doi.org/10.1056/nejmoa032691
30 https://doi.org/10.1200/jco.1987.5.10.1559
31 https://doi.org/10.1200/jco.1997.15.2.808
32 https://doi.org/10.1200/jco.2000.18.16.2938
33 https://doi.org/10.1200/jco.2004.09.046
34 https://doi.org/10.1200/jco.2005.00.232
35 https://doi.org/10.1200/jco.2005.03.0106
36 https://doi.org/10.1200/jco.2005.07.113
37 https://doi.org/10.1200/jco.2006.06.1317
38 https://doi.org/10.1200/jco.2007.14.9898
39 https://doi.org/10.1200/jco.2007.14.9930
40 https://doi.org/10.1200/jco.2008.26.15_suppl.4010
41 https://doi.org/10.1200/jco.2009.23.4344
42 https://doi.org/10.1200/jco.2012.42.5355
43 https://doi.org/10.1200/jco.2012.43.6535
44 schema:datePublished 2013-10
45 schema:datePublishedReg 2013-10-01
46 schema:description PURPOSE: Continuous treatment with FOLFOX therapy is associated with peripheral nerve toxicity, and to improve this inconvenient side effect various methods of administration are being investigated. A regimen of intermittent oxaliplatin administration by continuous infusion therapy, i.e., modified FOLFOX7 (mFOLFOX7) + bevacizumab, was designed with the goal of alleviating severe peripheral nerve disorders and hematological toxicity. A phase II clinical study was conducted to evaluate the efficacy and safety of this regimen. METHODS: Previously untreated patients were assigned to mFOLFOX7 (oxaliplatin 85 mg/m(2), levofolinate [l-LV] 200 mg/m(2), 5-fluorouracil [5-FU] 2400 mg/m(2)) + bevacizumab (5 mg/kg) administered every 2 weeks for 8 cycles, maintenance without oxaliplatin for 8 cycles, and reintroduction of mFOLFOX7 + bevacizumab for 8 cycles or until disease progression. Progression free survival (PFS) following the first dose (PFS 1) and following reintroduction of oxaliplatin (PFS 2) were used as indices for assessing the efficacy of intermittent administration. RESULTS: Fifty-two patients were enrolled, with median age of 64 years (range, 36-74). Median PFS 1 was 11.8 months (95 % confidence interval [CI], 9.5 to 13.7), median time to treatment failure was 10.3 months (95 % CI, 5.6 to 12.1), percentage of patients with neutropenia of grade 3 or higher was 7.8 %, and percentage with peripheral nerve disorders was 3.9 %. Response rate was 50 %, and 84.4 % of patients who started modified simplified LV5FU2 + bevacizumab were reintroduced to oxaliplatin. CONCLUSION: By excluding 5-FU bolus administration and administering bevacizumab continuously the mFOLFOX7 + bevacizumab regimen with preplanned withdrawal of oxaliplatin showed high tolerability and prevented severe peripheral neuropathy and neutropenia without reducing efficacy.
47 schema:genre research_article
48 schema:inLanguage en
49 schema:isAccessibleForFree true
50 schema:isPartOf N131192ee2c2d422282b9016034dfcb49
51 Nde75393630d241059be5747314d37da9
52 sg:journal.1094201
53 schema:name Phase II clinical study of modified FOLFOX7 (intermittent oxaliplatin administration) plus bevacizumab in patients with unresectable metastatic colorectal cancer—CRAFT study
54 schema:pagination 1321-1329
55 schema:productId N175d248499984f198f9c70e0208df2ae
56 N369181b358fc418a9c994d62606c39fc
57 N4f7db1f649ab41d5bdf8e2a86d909188
58 N59f4ca0dcb4c414ab571f188a3df54a9
59 N71fa739a137b4b9fba973930bd4b348b
60 schema:sameAs https://app.dimensions.ai/details/publication/pub.1031173929
61 https://doi.org/10.1007/s10637-013-9982-3
62 schema:sdDatePublished 2019-04-11T13:07
63 schema:sdLicense https://scigraph.springernature.com/explorer/license/
64 schema:sdPublisher Ncdf72bb9443843e7b9007d44850ed614
65 schema:url http://link.springer.com/10.1007%2Fs10637-013-9982-3
66 sgo:license sg:explorer/license/
67 sgo:sdDataset articles
68 rdf:type schema:ScholarlyArticle
69 N0343742df6b0414dbe50706b23ca137e schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
70 schema:name Fluorouracil
71 rdf:type schema:DefinedTerm
72 N0c518c56dc724dcfa4425a348c25bf35 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
73 schema:name Female
74 rdf:type schema:DefinedTerm
75 N111e82d523a54ead8a5bb6d22b2124e2 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
76 schema:name Antineoplastic Combined Chemotherapy Protocols
77 rdf:type schema:DefinedTerm
78 N131192ee2c2d422282b9016034dfcb49 schema:issueNumber 5
79 rdf:type schema:PublicationIssue
80 N162bd330f0a3431a9455d52d9cf74cfb rdf:first sg:person.01275733574.41
81 rdf:rest Nf3f68eb33ca143e385e6b8c470854f4a
82 N175d248499984f198f9c70e0208df2ae schema:name doi
83 schema:value 10.1007/s10637-013-9982-3
84 rdf:type schema:PropertyValue
85 N203a8f1a49d44994ac680c679938f003 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
86 schema:name Organoplatinum Compounds
87 rdf:type schema:DefinedTerm
88 N30e4870af4f14cfaa316db76d09ef551 rdf:first sg:person.011026272202.54
89 rdf:rest N6fa0dbd03528428194a884e94238b205
90 N35e592a850804e2bac311eec45ff3fbc schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
91 schema:name Male
92 rdf:type schema:DefinedTerm
93 N35ec8ca753c04f33ae5d9c8665a7e0dc rdf:first sg:person.01125146312.67
94 rdf:rest Nf61a4e5bc01645659c2ed8464ed0acb9
95 N369181b358fc418a9c994d62606c39fc schema:name readcube_id
96 schema:value 94827cb9097beeddc89a47c84459e341555e1f92cbbe82b41ceebba7a6ad7529
97 rdf:type schema:PropertyValue
98 N3c79b902930e4320ae24ab581a21321f schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
99 schema:name Liver Neoplasms
100 rdf:type schema:DefinedTerm
101 N3d41f0924b0c4a6e8af99257b178b4ad schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
102 schema:name Humans
103 rdf:type schema:DefinedTerm
104 N42d1c24e0cc043eeb67327cef8ca21f1 schema:name Department of Surgery, Saishukan Hospital, Aichi, Japan
105 rdf:type schema:Organization
106 N4f4c20cd5e2d4364a7a397a86ce19c2f schema:affiliation N42d1c24e0cc043eeb67327cef8ca21f1
107 schema:familyName Kawasaki
108 schema:givenName Shingo
109 rdf:type schema:Person
110 N4f7db1f649ab41d5bdf8e2a86d909188 schema:name nlm_unique_id
111 schema:value 8309330
112 rdf:type schema:PropertyValue
113 N50fd1a2207ac413286e87f304e92a76f rdf:first sg:person.0765430572.94
114 rdf:rest Nb4d2a774f7574264bb4dd5d76aaae1e2
115 N54e1f49b50c84e11a678d0b85967764d rdf:first sg:person.01222363707.85
116 rdf:rest N50fd1a2207ac413286e87f304e92a76f
117 N55d0a66af6b741e28b4f601890e218e5 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
118 schema:name Lung Neoplasms
119 rdf:type schema:DefinedTerm
120 N59f4ca0dcb4c414ab571f188a3df54a9 schema:name dimensions_id
121 schema:value pub.1031173929
122 rdf:type schema:PropertyValue
123 N65272cc743b94695bb1bf8cfa2e2c43c schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
124 schema:name Treatment Outcome
125 rdf:type schema:DefinedTerm
126 N6a606ecabdfa45a8bd7090e18757470f schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
127 schema:name Disease-Free Survival
128 rdf:type schema:DefinedTerm
129 N6f904dd56ad7448886960bd2270d3d1a schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
130 schema:name Angiogenesis Inhibitors
131 rdf:type schema:DefinedTerm
132 N6fa0dbd03528428194a884e94238b205 rdf:first sg:person.01154202243.44
133 rdf:rest N35ec8ca753c04f33ae5d9c8665a7e0dc
134 N71fa739a137b4b9fba973930bd4b348b schema:name pubmed_id
135 schema:value 23817973
136 rdf:type schema:PropertyValue
137 N95e0a2ad48e449c4a5c2f0ac0e3f5742 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
138 schema:name Adult
139 rdf:type schema:DefinedTerm
140 Na9d04cb2abbf45f985c4af9c6c81580b rdf:first sg:person.0647155176.80
141 rdf:rest rdf:nil
142 Naaf87db767be4f6a823af33d7331f5bf schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
143 schema:name Aged
144 rdf:type schema:DefinedTerm
145 Nb4d2a774f7574264bb4dd5d76aaae1e2 rdf:first sg:person.0673305153.34
146 rdf:rest Na9d04cb2abbf45f985c4af9c6c81580b
147 Nc03ea8a03e684531a685bd1ea36280b2 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
148 schema:name Middle Aged
149 rdf:type schema:DefinedTerm
150 Ncdf72bb9443843e7b9007d44850ed614 schema:name Springer Nature - SN SciGraph project
151 rdf:type schema:Organization
152 Nd1b7291f816740e5bb558b311a079f70 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
153 schema:name Lymphatic Metastasis
154 rdf:type schema:DefinedTerm
155 Nd920c986b4b144829c6178afbffad324 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
156 schema:name Peritoneal Neoplasms
157 rdf:type schema:DefinedTerm
158 Nde6fbffef5094286829fafdbb2dbd897 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
159 schema:name Leucovorin
160 rdf:type schema:DefinedTerm
161 Nde75393630d241059be5747314d37da9 schema:volumeNumber 31
162 rdf:type schema:PublicationVolume
163 Ne7f84f811c7c45c9940e359b092adde4 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
164 schema:name Bevacizumab
165 rdf:type schema:DefinedTerm
166 Nf313e985d68946dbbda2982ce0ac8a89 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
167 schema:name Colorectal Neoplasms
168 rdf:type schema:DefinedTerm
169 Nf342520becfb4d0e95b91bfc8fdb7199 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
170 schema:name Antibodies, Monoclonal, Humanized
171 rdf:type schema:DefinedTerm
172 Nf3f68eb33ca143e385e6b8c470854f4a rdf:first sg:person.01217410624.11
173 rdf:rest N30e4870af4f14cfaa316db76d09ef551
174 Nf61a4e5bc01645659c2ed8464ed0acb9 rdf:first N4f4c20cd5e2d4364a7a397a86ce19c2f
175 rdf:rest N54e1f49b50c84e11a678d0b85967764d
176 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
177 schema:name Medical and Health Sciences
178 rdf:type schema:DefinedTerm
179 anzsrc-for:1103 schema:inDefinedTermSet anzsrc-for:
180 schema:name Clinical Sciences
181 rdf:type schema:DefinedTerm
182 sg:journal.1094201 schema:issn 0167-6997
183 1573-0646
184 schema:name Investigational New Drugs
185 rdf:type schema:Periodical
186 sg:person.011026272202.54 schema:affiliation https://www.grid.ac/institutes/grid.415020.2
187 schema:familyName Ishida
188 schema:givenName Hideyuki
189 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.011026272202.54
190 rdf:type schema:Person
191 sg:person.01125146312.67 schema:affiliation https://www.grid.ac/institutes/grid.471500.7
192 schema:familyName Matsuoka
193 schema:givenName Hiroshi
194 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01125146312.67
195 rdf:type schema:Person
196 sg:person.01154202243.44 schema:affiliation https://www.grid.ac/institutes/grid.265050.4
197 schema:familyName Ooshiro
198 schema:givenName Mitsuru
199 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01154202243.44
200 rdf:type schema:Person
201 sg:person.01217410624.11 schema:affiliation https://www.grid.ac/institutes/grid.143643.7
202 schema:familyName Hamada
203 schema:givenName Chikuma
204 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01217410624.11
205 rdf:type schema:Person
206 sg:person.01222363707.85 schema:affiliation https://www.grid.ac/institutes/grid.411234.1
207 schema:familyName Mishima
208 schema:givenName Hideyuki
209 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01222363707.85
210 rdf:type schema:Person
211 sg:person.01275733574.41 schema:affiliation https://www.grid.ac/institutes/grid.412406.5
212 schema:familyName Tezuka
213 schema:givenName Tohru
214 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01275733574.41
215 rdf:type schema:Person
216 sg:person.0647155176.80 schema:affiliation https://www.grid.ac/institutes/grid.412406.5
217 schema:familyName Koda
218 schema:givenName Keiji
219 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0647155176.80
220 rdf:type schema:Person
221 sg:person.0673305153.34 schema:affiliation https://www.grid.ac/institutes/grid.460103.0
222 schema:familyName Sakamoto
223 schema:givenName Junichi
224 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0673305153.34
225 rdf:type schema:Person
226 sg:person.0765430572.94 schema:affiliation https://www.grid.ac/institutes/grid.471500.7
227 schema:familyName Maeda
228 schema:givenName Kotaro
229 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0765430572.94
230 rdf:type schema:Person
231 sg:pub.10.1007/s10637-011-9779-1 schema:sameAs https://app.dimensions.ai/details/publication/pub.1023072546
232 https://doi.org/10.1007/s10637-011-9779-1
233 rdf:type schema:CreativeWork
234 sg:pub.10.1038/bjc.2011.201 schema:sameAs https://app.dimensions.ai/details/publication/pub.1017729876
235 https://doi.org/10.1038/bjc.2011.201
236 rdf:type schema:CreativeWork
237 sg:pub.10.1038/sj.bjc.6600467 schema:sameAs https://app.dimensions.ai/details/publication/pub.1041567656
238 https://doi.org/10.1038/sj.bjc.6600467
239 rdf:type schema:CreativeWork
240 https://app.dimensions.ai/details/publication/pub.1074766959 schema:CreativeWork
241 https://doi.org/10.1016/s0140-6736(00)02034-1 schema:sameAs https://app.dimensions.ai/details/publication/pub.1006410174
242 rdf:type schema:CreativeWork
243 https://doi.org/10.1056/nejmoa032691 schema:sameAs https://app.dimensions.ai/details/publication/pub.1014051315
244 rdf:type schema:CreativeWork
245 https://doi.org/10.1200/jco.1987.5.10.1559 schema:sameAs https://app.dimensions.ai/details/publication/pub.1078843412
246 rdf:type schema:CreativeWork
247 https://doi.org/10.1200/jco.1997.15.2.808 schema:sameAs https://app.dimensions.ai/details/publication/pub.1083054579
248 rdf:type schema:CreativeWork
249 https://doi.org/10.1200/jco.2000.18.16.2938 schema:sameAs https://app.dimensions.ai/details/publication/pub.1074684744
250 rdf:type schema:CreativeWork
251 https://doi.org/10.1200/jco.2004.09.046 schema:sameAs https://app.dimensions.ai/details/publication/pub.1051354561
252 rdf:type schema:CreativeWork
253 https://doi.org/10.1200/jco.2005.00.232 schema:sameAs https://app.dimensions.ai/details/publication/pub.1013477854
254 rdf:type schema:CreativeWork
255 https://doi.org/10.1200/jco.2005.03.0106 schema:sameAs https://app.dimensions.ai/details/publication/pub.1050440893
256 rdf:type schema:CreativeWork
257 https://doi.org/10.1200/jco.2005.07.113 schema:sameAs https://app.dimensions.ai/details/publication/pub.1046620703
258 rdf:type schema:CreativeWork
259 https://doi.org/10.1200/jco.2006.06.1317 schema:sameAs https://app.dimensions.ai/details/publication/pub.1036243573
260 rdf:type schema:CreativeWork
261 https://doi.org/10.1200/jco.2007.14.9898 schema:sameAs https://app.dimensions.ai/details/publication/pub.1027137405
262 rdf:type schema:CreativeWork
263 https://doi.org/10.1200/jco.2007.14.9930 schema:sameAs https://app.dimensions.ai/details/publication/pub.1029489307
264 rdf:type schema:CreativeWork
265 https://doi.org/10.1200/jco.2008.26.15_suppl.4010 schema:sameAs https://app.dimensions.ai/details/publication/pub.1079372980
266 rdf:type schema:CreativeWork
267 https://doi.org/10.1200/jco.2009.23.4344 schema:sameAs https://app.dimensions.ai/details/publication/pub.1026343555
268 rdf:type schema:CreativeWork
269 https://doi.org/10.1200/jco.2012.42.5355 schema:sameAs https://app.dimensions.ai/details/publication/pub.1049732450
270 rdf:type schema:CreativeWork
271 https://doi.org/10.1200/jco.2012.43.6535 schema:sameAs https://app.dimensions.ai/details/publication/pub.1013021486
272 rdf:type schema:CreativeWork
273 https://www.grid.ac/institutes/grid.143643.7 schema:alternateName Tokyo University of Science
274 schema:name Faculty of Engineering, Tokyo University of Science, Tokyo, Japan
275 rdf:type schema:Organization
276 https://www.grid.ac/institutes/grid.265050.4 schema:alternateName Toho University
277 schema:name Department of Surgery, Toho University Sakura Medical Center, Chiba, Japan
278 rdf:type schema:Organization
279 https://www.grid.ac/institutes/grid.411234.1 schema:alternateName Aichi Medical University
280 schema:name Aichi Medical University Cancer Center, Aichi, Japan
281 rdf:type schema:Organization
282 https://www.grid.ac/institutes/grid.412406.5 schema:alternateName Teikyo University Chiba Medical Center
283 schema:name Department of Surgery, Teikyo University Chiba Medical Center, 3426-3 Anesaki, 299-0111, Ichihara City, Chiba, Japan
284 rdf:type schema:Organization
285 https://www.grid.ac/institutes/grid.415020.2 schema:alternateName Jichi Medical University Saitama Medical Center
286 schema:name Department of Digestive Tract and General Surgery, Saitama Medical Center, Saitama Medical University, Saitama, Japan
287 rdf:type schema:Organization
288 https://www.grid.ac/institutes/grid.460103.0 schema:alternateName Tokai Central Hospital
289 schema:name Tokai Central Hospital, Gifu, Japan
290 rdf:type schema:Organization
291 https://www.grid.ac/institutes/grid.471500.7 schema:alternateName Fujita Health University Hospital
292 schema:name Department of Surgery, Fujita Health University Hospital, Aichi, Japan
293 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...